SethOFagbemiMD

Clinical Assistant Professor, Department of Medicine-University of Wisconsin School of Medicine and Public Health Madison, WI

Join to view full profile

Dr. Fagbemi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Fagbemi's full profile

Already have an account?

Office
220 24th St S
Wisconsin Rapids, WI 54494
Phone+1 715-387-5416

Fax+1 715-221-8940
Is this information wrong?

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1995 - 1998
Cook County Health and Hospitals SystemResidency, Internal Medicine, 1992 - 1995
University of IbadanClass of 1982

Certifications & Licensure

WI State Medical License 1993 - 2025
MI State Medical License 1998 - 2009
IL State Medical License 1992 - 2002
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
Active, not recruiting
Phase 3
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2009 Jul 02
Completed
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma Start of enrollment: 2010 Apr 01
Completed
Phase 2
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Jan 24
Active, not recruiting
Phase 2
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer Start of enrollment: 2017 Mar 31
Active, not recruiting
Phase 2
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer Start of enrollment: 2020 Mar 03
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) as a Neoadjuvant Chemotherapy for Non-metastatic Esophageal Cancer (nMEC)
Adedayo A. Onitilo, Trista J. Stankowski-Drengler, Oyewale Shiyanbola, Jessica M. Engel, Sabo Tanimu, Seth O. Fagbemi, Ya-Huei Li> ;Clinical Medicine & Research. 2021 Mar 31
5 citations
Community experience with bortezomib in patients with multiple myeloma.
Adedayo A. Onitilo, Jessica M. Engel, Bankole Olatosi, Seth O. Fagbemi> ;American Journal of Hematology. 2007 Jul 1
[New chemotherapy regimens for advanced bladder cancer].
Fagbemi, S. O., Stadler, W. M.> ;Actas Urol Esp. 1998 Jun
New chemotherapy regimens for advanced bladder cancer.
Fagbemi, S. O., Stadler, W. M.> ;Semin Urol Oncol. 1998 Feb
Phorbol ester-induced ventricular fibrillation in the Langendorff-perfused rabbit heart: antagonism by staurosporine and glibenclamide.
Black, S. C., Fagbemi, S. O., Chi, L., Friedrichs, G. S., Lucchesi, B. R.> ;J Mol Cell Cardiol. 1993 Dec
Computerized tomographic findings in adolescent and adult Nigerian epileptics.
Ogunniyi, A., Adeyinka, A., Fagbemi, S. O., Orere, R., Falope, Z. F., Oyawole, S. O.> ;West Afr J Med. 1994 Apr 01
Antifibrillatory and profibrillatory actions of selected class I antiarrhythmic agents.
Fagbemi, S. O., Chi, L., Lucchesi, B. R.> ;J Cardiovasc Pharmacol. 1993 May
Actions of pinacidil at a reduced potassium concentration: a direct cardiac effect possibly involving the ATP-dependent potassium channel.
Chi, L., Black, S. C., Kuo, P. I., Fagbemi, S. O., Lucchesi, B. R.> ;J Cardiovasc Pharmacol. 1993 Feb
The effect of aspirin, indomethacin and sodium meclofenamate on coronary artery ligation arrhythmias in anaesthetized rats.
Fagbemi, S. O.> ;Eur J Pharmacol. 1984 Jan 27
The effects of prazosin, phentolamine and phenoxybenzamine on inhibitory alpha-adrenoceptors in the guniea-pig isolated ileum.
Fagbemi, S. O., Salako, L. A.> ;Br J Pharmacol. 1982 Jun
The effect of prazosin on the guinea-pig ileum.
Fagbemi, S. O., Salako, L. A.> ;Br J Pharmacol. 1980 Nov
Enzymes in normally perfused and ischaemic dog hearts which release a substance with kinin like activity.
Zeitlin, I. J., Fagbemi, S. O., Parratt, J. R.> ;Cardiovasc Res. 1989 Feb
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

Marshfield Medical CenterMarshfield, Wisconsin
Gundersen Moundview Hospital & ClinicsFriendship, Wisconsin